Literature DB >> 24716397

Glycogen storage disease type III in Israel: presentation and long-term outcome.

Eli Hershkovitz, Itay Forschner, Hanna Mandel, Ronen Spiegel, Tally Lerman-Sagie, Yair Anikster, A Zeharia, Shimon Moses.   

Abstract

Glycogen storage disease type III (GSD III) was found in the past with an unusual frequency among North African Jews in Israel. The aim of this study was to review the long-term clinical course of GSD III's patients in Israel. Relevant pediatric and adult clinical units of all Israeli hospitals were approached to report on their GSD III patients. 21 (14 M/7F) live patients were located. The average age of the patients was nearly twenty years. Eleven patients were older than 18 years of age. 76% of the patients were of Jewish North African origin, 14% of Jewish European origin, and 10% were Arab Muslims. The symptoms at presentation were fasting, hypoglycemia, hepatomegaly slight hypotonia in infancy and delayed growth. Although in most of the patients their signs and symptoms ameliorated after childhood, significant complications were observed in some 20% of the patients. Consequently, a life long follow up of GSD-III patients is required.

Entities:  

Mesh:

Year:  2014        PMID: 24716397

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  3 in total

1.  Does type I truly dominate hepatic glycogen storage diseases in Korea?: a single center study.

Authors:  Yu Ju Jeong; Ben Kang; So Yoon Choi; Chang-Seok Ki; Soo-Youn Lee; Hyung-Doo Park; Yon Ho Choe
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2014-12-31

2.  A founder splice site mutation underlies glycogen storage disease type 3 in consanguineous Saudi families.

Authors:  Sulman Basit; Omhani Malibari; Alia Mahmood Al Balwi; Firoz Abdusamad; Feras Abu Ismail
Journal:  Ann Saudi Med       Date:  2014 Sep-Oct       Impact factor: 1.526

3.  A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease.

Authors:  Han-Hyuk Lim; Haiqing Yi; Takashi K Kishimoto; Fengqin Gao; Baodong Sun; Priya S Kishnani
Journal:  Mol Genet Metab Rep       Date:  2017-07-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.